Following publication of the original article , the author reported errors in the formatting of the table. The details of the errors are as follows: In Table 1, the data presented do not correspond to the row title: The education row currently contains incorrect data. The weight row currently contains the years of education. The APOE 4 genotype row currently contains the weight data. In Table 1, the data should be displayed as follows: Variable Intention-to-treat population (n = 797) Placebo (n = 266) Gantenerumab 105 mg (n = 271) Gantenerumab 225 mg (n = 260) Age, years, mean (SD) 69.5 (7.5) 70.3 (7.0) 71.3 (7.1) Education, years, mean (SD) 12.6 (4.3)12.9 (4.8) 12.1 (4.5) Weight, kg, mean (SD) 69.8 (12.9) 70.5 (13.6) 70.1 (12.5) APOE4 genotype, %a.
Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F.
, Nikolcheva, T., ... Fontoura, P. (2018). Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease (Alzheimer's Research and Therapy (2017) 9 (95) DOI: 10.1186/s13195-017-0318-y)
. Alzheimer's Research and Therapy
(1), . https://doi.org/10.1186/s13195-018-0409-4